Aquatic Capital Management LLC Buys 61,927 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

Aquatic Capital Management LLC grew its holdings in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 52.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 180,927 shares of the company's stock after purchasing an additional 61,927 shares during the period. Aquatic Capital Management LLC's holdings in Takeda Pharmaceutical were worth $2,395,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Versant Capital Management Inc acquired a new position in Takeda Pharmaceutical in the fourth quarter worth approximately $26,000. Wilmington Savings Fund Society FSB acquired a new stake in shares of Takeda Pharmaceutical during the third quarter worth $40,000. Farther Finance Advisors LLC lifted its holdings in shares of Takeda Pharmaceutical by 123.6% during the fourth quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company's stock valued at $47,000 after purchasing an additional 1,976 shares during the last quarter. Crowley Wealth Management Inc. acquired a new position in shares of Takeda Pharmaceutical in the 4th quarter valued at $52,000. Finally, Cromwell Holdings LLC purchased a new position in Takeda Pharmaceutical in the 4th quarter worth about $61,000. Institutional investors and hedge funds own 9.17% of the company's stock.

Analysts Set New Price Targets

Separately, Morgan Stanley upgraded shares of Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a report on Wednesday, April 2nd.

Takeda Pharmaceutical Trading Down 1.7 %

NYSE TAK traded down $0.27 on Thursday, hitting $15.03. 1,674,582 shares of the stock were exchanged, compared to its average volume of 1,871,175. The company's 50-day moving average price is $14.81 and its two-hundred day moving average price is $13.96. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.31 and a quick ratio of 0.72. Takeda Pharmaceutical Company Limited has a 52-week low of $12.58 and a 52-week high of $15.37. The company has a market capitalization of $47.81 billion, a price-to-earnings ratio of 37.56, a P/E/G ratio of 0.24 and a beta of 0.39.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last posted its quarterly earnings results on Thursday, January 30th. The company reported $0.42 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. Research analysts predict that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.